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Background: The role of pERK, pAKT and p53 as biomarkers in patients with advanced pancreatic cancer has not
yet been defined.
Methods: Within the phase III study AIO-PK0104 281 patients with advanced pancreatic cancer received an
erlotinib-based 1st-line regimen. Archival tissue from 153 patients was available for central immunohistochemistry
staining for pERK, pAKT and p53. Within a subgroup analysis, biomarker data were correlated with efficacy endpoints
and skin rash using a Cox regression model.
Results: Fifty-five out of 153 patients were classified as pERKlow and 98 patients as pERKhigh; median overall survival
(OS) was 6.2 months and 5.7 months, respectively (HR 1.29, p = 0.16). When analysing pERK as continuous variable,
the pERK score was significantly associated with OS (HR 1.06, 95% CI 1.0-1.12, p = 0.05). Twenty-one of 35 patients
were pAKTlow and 14/35 pAKThigh with a corresponding median OS of 6.4 months and 6.8 months, respectively
(HR 1.03, p = 0.93). Four out of 50 patients had a complete loss of p53 expression, 20 patients a regular expression
and 26 patients had tumors with p53 overexpression. The p53 status had no impact on OS (p = 0.91); however, a
significant improvement in progression-free survival (PFS) (6.0 vs 1.8 months, HR 0.24, p = 0.02) and a higher rate of
skin rash (84% vs 25%, p = 0.02) was observed for patients with a regular p53 expression compared to patients with
a complete loss of p53.
Conclusion: pERK expression may have an impact on OS in erlotinib-treated patients with advanced pancreatic
cancer; p53 should be further investigated for its potential role as a predictive marker for PFS and skin rash.
Trial registration: NCT00440167 (registration date: February 22, 2007).
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Despite significant efforts in clinical research in pancreatic
cancer during the last decade, only moderate progress has
been achieved. Main steps forward were generated with the
introduction of adjuvant chemotherapy as a standard of
care after curative-intent resection (yielding in a potential
long-term survival or even cure in about 20% of patients
resected) and more recently, with the introduction of novel
combination chemotherapy regimens (e.g. FOLFIRINOX
and gemcitabine/nab-paclitaxel) for the treatment of
metastatic disease [1,2]. However, several large phase III
trials investigating targeted agents (in unselected patient
populations) have failed with only erlotinib (in addition
to standard gemcitabine) achieving a moderate gain in
overall survival (OS) [3,4].
To date, no validated tissue biomarker is available that
would allow a prognostic patient stratification or even
the prediction of treatment efficacy in pancreatic cancer.
Several molecular predictive markers like the human
equilibrative nucleoside transporter 1 (hENT1; for the
efficacy of gemcitabine) and secreted protein acidic and
rich in cysteine (SPARC; for nab-paclitaxel) are currently
under investigation with in part inconclusive results up
to now [3,5,6]. Regarding the use of EGFR targeting
agents in advanced pancreatic cancer, the tumor KRAS
status may play a role as a prognostic or even predictive
biomarker: based on previous translational results from
AIO-PK0104, a large randomized phase III trial comparing
a treatment sequence of gemcitabine + erlotinib followed
by capecitabine vs capecitabine + erlotinib followed by
gemcitabine in patients with advanced disease, patients
with a KRAS wildtype may have a prolonged survival
compared to patients with KRAS exon 2 mutations
[7]. Other groups have confirmed these data, and the work
of Kim and colleagues even suggested that KRAS may serve
as a predictive biomarker for the efficacy of erlotinib [8,9].
Based on previous analyses conducted on archival formalin
fixed paraffin embedded (FFPE) tissue from AIO-PK014 no
other marker besides KRAS showed a correlation with
survival endpoints or objective response: data on EGFR
protein expression, EGFR gene amplification, PTEN
expression and on EGFR intron 1 polymorphism did
not show - despite previous pre-clinical evidence - a
correlation with efficacy study endpoints [10-12].
We thus decided to additionally analyze downstream
targets of the EGFR pathway, namely phospho-ERK (pERK)
and phospho-AKT (pAKT) as potential biomarkers in
advanced pancreatic cancer. Both represent effector
molecules in the EGFR downstream signalling network,
pERK for the RAS/RAF/MEK cascade and pAKT is
involved in the PI3K/mTOR pathway [13,14]. Previous
evidence (mainly derived from surgical series and/or
in non-erlotinib treated patients) suggests a potential
role of pERK and pAKT in pancreatic cancer biologyand both markers additionally may represent a more
appropriate way to assess EGFR pathway activation
compared to single upstream markers like EGFR itself
[14-17]. As increasing pre-clinical evidence from mouse
models and also from genome-wide analyses revealed an
important role of p53 in the pathogenesis of pancreatic
cancer the investigators decided to also include this
marker in the current translational analysis from
AIO-PK0104 [18,19]. This decision specifically was also
based on recent data showing a potential interaction of
p53 with KRAS signalling [19].
The aim of this retrospective translational biomarker
study based on the prospective AIO-PK0104 trial thus
was to determine the frequency of alterations in pERK,
pAKT and p53 in erlotinib treated patients with advanced
pancreatic cancer, as well as to investigate if there is a
correlation of biomarker data with efficacy (progression-free
survival, PFS and OS) and safety endpoints (skin rash)
from the clinical data set.Methods
Translational patient population
Adult patients (18 to 75 years) with a histologically or
cytologically confirmed diagnosis of treatment-naïve,
advanced exocrine pancreatic cancer (stage III and IV) were
eligible for AIO-PK0104. Overall, 281 patients were
randomized and 274 patients were eligible for the intention-
to-treat (ITT) population; detailed results from the clinical
study have been published in 2013 [7]. Archival FFPE
tissue, which was obtained during routine pre-therapeutic
diagnostic procedures, was requested retrospectively from
the participating centers/pathologists for the translational
study. Cytological specimens were not included. FFPE
histological tissue was accepted independent of its origin,
e.g. surgical or biopsy specimens from primary pancreatic
tumor, lymph nodes or distant metastases. The study had
approval of the local ethical committees in all participating
German centers (see Additional file 1: Table S1) and
patients gave written informed consent prior to any
study-specific procedure. This study was conducted
according to GCP/ICH guidelines and according to the
Declaration of Helsinki and was registered at ClinicalTrials.
gov, number NCT00440167.Analyses of molecular tissue biomarkers
The current translational analyses from AIO-PK0104
were performed at the Ludwig-Maximilians-University of
Munich by SO and TK (pERK), at the Technical University
of Munich by JTS, AMS and IE (pAKT and p53/TP53) as
well as at the University of Tübingen by BS (p53). All
available FFPE tumor blocks were checked for quality,
tissue integrity and tumor content (HE staining) by a path-
ologist (SO) in a blinded manner. All involved pathologists
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study results.
Immunohistochemistry
Immunohistochemistry (IHC) was performed on a
Ventana Benchmark XT autostainer using the XT
UltraView diaminobenzidine kit (Ventana Medical
Systems, Oro Valley, AZ, USA). The primary antibodies
were as follows: monoclonal anti-pERK1/2 antibody
(rabbit anti-phospho-p44/42 MAPK [Thr202/Tyr204]
clone 20G11, Cell Signaling Technology, Danvers, MA,
USA), anti-pAKT (Santa Cruz, sc-135650, 1:30, heat
mediated antigen retrieval) and anti-p53 (Novocastra,
DO-7, 1:200, heat mediated antigen retrieval).
pERK expression
For the examination of pERK IHC a scoring system analo-
gously to a score developed for PTEN by Loupakis et al.
was applied [20]: the nuclear and cytoplasmic staining
intensity (0 - no, 1 - weak, 2 - moderate, and 3 - strong
staining) were added to the score for the percentage of
positive cells (0 - negative, 1 - less than 25%, 2 - 25%
to 50%, 3 - more than 50% positive staining cells) and
finally nuclear and cytoplasmic score were summa-
rized (score 0–12; see Additional file 2: Figure S1).
Specimens were defined as pERKhigh if the total score
was 6 or higher.
pAKT expression
Cytoplasmatic and nuclear pAKT expression by IHC in
tumor cells was scored analogously to the pERK score
described above. If the score was 5 or higher, samples
were defined as pAKThigh. Cases that exhibited no staining
in stromal or inflammatory cells (as internal controls)
were omitted (see Additional file 3: Figure S2, D-F).
p53 expression
p53 expression has been evaluated as completely lost
(no reaction in tumor cells but positive internal control),
variable (no to strong) nuclear expression as normal
and diffusely strong as aberrant overexpression (see
Additional file 3: Figure S2, A-C).
TP53 mutational analysis
The investigators additionally selected 12 good- and
poor-risk study patients based on clinical data for objective
response and time-to-treatment failure for 1st-line therapy
(TTF1, a pre-defined study endpoint [7]) in order to
analyze the TP53 mutation status (exon 5 to 8) by Sanger
sequencing. The following primers were used: Ex-5 F:ATC
TGT TCA CTT GTG CCC TG, Ex-5R:AAC CAG CCC
TGT CGT CTC TC, Ex-6 F.AGG GTC CCC AGG CCT
CTG AT, Ex-6R:CAC CCT TAA CCC CTC CTC CC,
Ex-7 F:CCA AGG CGC ACT GGC CTC ATC, Ex-7R:CAG AGG CTG GGG CAC AGC AGG, Ex-8 F.TTC
CTT ACT GCC TCT TGC TT and Ex-8R:TGT CCT
GCT TGC TTA CCT CG.
Statistical analyses
All statistical analyses for the translational study of the
AIO-PK0104 trial were performed centrally at the
Ludwig-Maximilians-University of Munich, Institute of
Medical Informatics, Biometry and Epidemiology by
RPL. Translational biomarker data were correlated with
efficacy (PFS and OS) and safety study endpoints (skin rash)
using univariate analyses. As appropriate, biomarker
results were handled as dichotomous/categorical variables
(e.g. pAKTlow vs pAKThigh, p53 expression) or as continu-
ous variables (e.g. linear scoring system 0 to 12 for pERK).
Time-to-event endpoints were analyzed with the
Kaplan-Meier method; differences were compared using
the log-rank test with a 2-sided p-value of ≤0.05 being
regarded as statistically significant.
Results
Patient characteristics
For the current analysis, FFPE tumor blocks were initially
available from 153 of the 281 randomized patients. The
ITT study population consisted of 274 eligible patients,
and 153 patients were selected for the current translational
patient population; detailed patient characteristics are
summarized in Table 1. With regard to important baseline
parameters (e.g. age, gender, stage of disease, performance
status), no significant imbalances between the ITT
population and the translational study population were
apparent.
Frequency of alterations in pERK, pAKT and p53 and their
correlation with efficacy endpoints
Within Table 2, each of the 3 analysed markers was
categorized as a dichotomous variable and a correlation
between selected baseline patient characteristics and
molecular marker results was performed. No significant
differences were obvious for the biomarker results based
on clinical characteristics; of note, although the numbers
were small, all 4 patients with a p53 loss had a good
pre-treatment performance status and 2 of them (50%)
had locally advanced disease (whereas in patients with
regular p53 expression only 5% had locally advanced
pancreatic cancer).
pERK
pERK IHC staining was performed on 153 samples,
classifying 55 patients as pERKlow (36%) and 98 patients as
pERKhigh (64%), with a median score level of 7 (range 0 to
12). pERK expression showed no correlation with KRAS
status (p = 0.32), EGFR protein expression (p = 0.38) or
EGFR gene amplification (p = 1.00), respectively. The pERK
Table 1 Baseline patient characteristics: Intention-to-treat population (n = 274) and translational study population (n = 153)
Parameter Intention-to-treat Translational
Gem + E (n = 143) Cap + E (n = 131) Gem + E (n = 85) Cap + E (n=68)
No. % No. % No. % No. %
Age [years]
Median 65 63 63 64
Range 32 - 78 38 - 75 32 - 75 42 - 75
Gender
Male 82 57 83 63 49 58 41 60
Female 61 43 48 37 36 42 27 40
Stage of disease
Locally advanced 21 15 22 17 13 15 13 19
Metastatic 122 85 109 83 72 85 55 81
Performance status
KPS 60-80% 50 35 49 37 29 34 30 44
KPS 90-100% 85 59 79 60 50 59 38 56
Missing 8 6 3 2 6 7 0 0
Previous surgery 8 6 17 13 7 8 8 12
Weight loss during three
months before
randomisation [kg]
Median 5 7 5.5 7
Range 0 - 47 0 - 45 0 - 20 0 - 35
Baseline CA 19–9 [U/ml]1
Median 1999 1756 2632 1255
Range 1 - 700000 1 - 1000000 2 - 700000 1 - 1000000
Abbreviations: Cap Capecitabine, E Erlotinib, Gem Gemcitabine, KPS Karnofsky performance status; 1n = 245 / 274.
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(p = 0.91). Median OS for patients classified as pERKlow
was 6.2 months compared to 5.7 months in the pERKhigh
group (HR 1.29, 95% CI 0.90-1.83; p = 0.16) (Table 3).
When analysing pERK as a continuous variable, an
increase in the hazard for death by a factor of 1.06 was
detected for each level of the pERK expression score of 0
to 12 (HR 1.06, 95% CI 1.0-1.12; p[log rank] = 0.050,
p[likelihood ratio] = 0.047). Within Figure 1, these data are
illustrated graphically by showing the predicted survival
probabilities (derived from a Cox model) based on 4
exemplary pERK IHC score levels.
pAKT
After analysing pERK and p53, samples with an adequate
amount of tumor tissue (for a usable pAKT IHC scoring)
were available from 35 patients only. Of those, 21
(60%) were classified as pAKTlow and 14 (40%) as
pAKThigh; the pAKT IHC score level in the analyzed
subgroup ranged from 2 to 10. As shown in Table 3, the
pAKT status had no significant impact on PFS or OS. Dueto the lower numbers, no analysis as a continuous variable
was performed for pAKT.
p53 immunohistochemistry and TP53 mutational analyses
A p53 status assessment by IHC could be carried out
successfully on 50 tumor samples: 4 patients (8%) had a
complete loss of p53 expression, 20 patients (40%) a regular
p53 expression and 26 patients (52%) a p53 overexpression,
respectively. In 43 analysable patients, p53 expression did
not correlate with the KRAS mutation status (wildtype vs
mutation; p = 0.32). Also no significant association between
p53 and the objective response rate to 1st-line treat-
ment was obvious (p = 0.26). The p53 expression had no
significant impact on OS (8.1 vs 7.0 vs 5.0 months,
p[global] = 0.91; Table 3 and Figure 2B); patients with
an intact p53 expression had a significantly prolonged
PFS (6.0 months) compared to patients with a loss of
p53 (1.8 months) or p53 overexpression (2.5 months;
p[global] = 0.03) (see Table 3 and Figure 2A).
We furthermore used archival DNA samples for
performing an additional post-hoc explorative analysis







pERKlow pERKhigh pAKTlow pAKThigh Loss Regular Overexpression
n = 55 n = 98 n = 21 n = 14 n = 4 n = 20 n = 26
n n n n n n n
Age [years]
Median 66 63 p = 0.45 64 61 p = 0.27 61 61 65 p = 0.50
Gender
Male 32 58 p = 1.00 12 7 p = 0.74 1 10 15 p = 0.48
Female 23 40 9 7 3 10 11
Stage of disease
Locally advanced 7 19 p = 0.37 1 1 p = 1.00 2 1 3 p = 0.08
Metastatic 48 79 20 13 2 19 23
Performance status
KPS 60-80% 23 36 p = 0.73 8 3 p = 0.46 0 4 12 p = 0.07
KPS 90-100% 31 57 13 11 4 16 14
CA 19–9 [U/ml]
Median 1118 2030 p = 0.19 1975 3154 p = 0.74 1894 3084 1539 p = 0.95
Treatment arm
Gem + E 27 58 p = 0.24 9 10 p = 0.17 2 12 14 p = 0.91
Cap + E 28 40 12 4 2 8 12
Abbreviations: Cap Capecitabine, E Erlotinib, Gem Gemcitabine, KPS Karnofsky performance status.
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we selected 12 good- and poor-risk patients and
performed TP53 sequencing of exons 5 to 8. Detailed
results of these analyses are summarized within Table 4:
we detected 6 missense mutations in 5 tumors, with one
additional silent mutation (R248R). All patients with a
prolonged disease control (TTF1 ≥ 10 months) had TP53Table 3 Correlation of biomarker results (dichotomous variab
(PFS) and overall survival (OS)
Biomarker n Median PFS
(Alteration) Mo. HR (95% CI)
p-ERK 153
pERKlow 55 3.1 1.01 (0.69-1.47)
pERKhigh 98 3.2
p-AKT 35




Regular 20 6.0 0.24 (0.08-0.79)
Overexpression 26 2.5 0.47 (0.16-1.40)
Abbreviations: CI Confidence interval, HR Hazard ratio, Mo Months.
(+global p value).wildtype tumors, with 1 tumor (case no. 33) carrying the
silent TP53 mutation R248R. However, we also found
patients that had a rapid disease progression (e.g. case no.
98) that was classified as TP53 wildtype. One patient
(case no. 99) had 2 mutations in exon 5 of p53 (T155I &
V137M) and was clinically characterized by a rapid disease
progression with a TTF1 of 0.5 months only (Table 4).les) with efficacy parameters: Progression-free survival
Median OS
p Mo. HR (95% CI) p
0.98 6.2 1.29 (0.90-1.83) 0.16
5.7




0.03+ 5.0 1.22 (0.42-3.57) 0.91+
Figure 1 Predicted overall survival (OS) probabilities (derived from a Cox model) based on the 4 exemplary pERK IHC score levels 0, 4,
9 and 12 (n = 153; p[log rank] = 0.050).
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Neither the pERK nor the pAKT status correlated
with the occurrence of skin rash (any grade I-III): the
corresponding data for each marker (analyzed as
dichotomous variable) are summarized in Table 5. Patients
with a loss of p53 in their tumor had a rash incidence
during treatment with erlotinib of only 25%, whereas
patients with a regular p53 expression had a rate for skin
rash of 84% (p[global] = 0.04).
Discussion
Based on translational data from controlled prospective
clinical trials no prognostic or predictive tissue biomarkers
have yet been defined in advanced pancreatic cancer. Some
large phase III studies investigating anti-EGFR treatment
strategies like erlotinib or cetuximab (in comparison to a
single-agent gemcitabine control arm) were - at least up to
now - not able to define prognostic or predictive
biomarkers [21,22]. Within the current translational
subgroup analysis of AIO-PK0104 we thus tried to
exploratively analyze if the EGFR pathway ‘downstream’
mediators pERK and pAKT could serve as biomarkers in
advanced pancreatic cancer. Previous evidence from
mainly small surgical series indicated that both pERK and
pAKT may have a biological role in pancreatic cancer,
however with in part inconclusive results on their
prognostic role [15-17]. Regarding pERK, 64% of the
153 analyzed tumor samples from AIO-PK0104 were
classified as pERKhigh; a significant impact on OS was found
when the pERK expression score (0 to 12) was analyzed as
a continuous variable (Figure 1). The observed HR of 1.06
(95% CI 1.0-1.12) reflects an increase in the hazard
for death by a factor of 1.06 for each level of the
pERK expression score of 0 to 12. If this associationis a prognostic or a predictive phenomenon remains
unclear, as all patients treated within AIO-PK0104 received
an erlotinib-containing 1st-line regimen [7]. Nevertheless,
based on the fact that the pERK status had no impact on
PFS or response, one might hypothesize that the observed
effect on OS is rather prognostic than predictive for the
efficacy of erlotinib. In contrast, the IHC expression
pattern of pAKT could successfully be determined in a
smaller subgroup of only 35 patients and showed no
impact on survival endpoints.
The potentially most interesting and hypothesis-generating
findings from the current translational analysis of
AIO-PK0104 are derived from the data on p53. The role
of the transcription factor p53 as a tumor suppressor in
several human cancers is well known; however its role as
a prognostic or predictive biomarker remains largely
unclear to date [23]. A loss of p53 is thought to stimulate
tumor growth and dissemination, whereas a regular p53
expression might be associated with a more favorable
disease biology. The biological role of a p53 overexpression
in human tumors still is not understood entirely. Currently
it also remains a matter of debate if p53 should be assessed
by IHC or by mutational analysis; most authors indeed
recommend combining IHC and gene-sequencing as the
most reliable prognostic tool [23]. Of the 50 samples from
our study cohort assessed for p53 by IHC, 4 showed a
complete loss, 20 a regular expression and 26 an overex-
pression. Interestingly, a loss of p53 and p53 overexpres-
sion were associated with a dismal PFS, but on the other
hand had no impact on OS (Table 3 and Figure 2). Thus
one might conclude (as postulated by other authors earlier)
that the overexpression status of p53 might lead to a func-
tional loss of p53 resulting in the same biological effects
like the absence of p53 expression by IHC. When we
AB
Figure 2 Correlation of efficacy endpoints with the p53 IHC expression level. A) Progression-free survival (PFS, n = 50; p[global] = 0.03).
B) Overall survival (OS, n = 50; p[global] = 0.91).
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skin rash (a well known side-effect of erlotinib and other
anti-EGFR drugs and a predictive ‘clinical marker’ for
drug efficacy) we found rash - of any grade - in 84% of the
patients whose tumor carried a regular p53 expression,
whereas only 25% of patients with a p53 loss developed
rash during treatment with erlotinib (p = 0.02). Thus one
might hypothesize a potential role for p53 as a biomarker
for rash and/or as a predictive marker for the efficacy of
erlotinib.
Based on the interesting p53 findings from the IHC
analyses, we additionally performed Sanger sequencing
of the TP53 gene (exon 5 to 8) in 12 selected good- and
poor-risk AIO-PK0104 study patients (see Table 4). Simul-
taneous p53 IHC data were unfortunately available in 4 out
of 12 patients only: two patients with TP53 wildtype
had a regular p53 expression, and 2 patients with a
TP53 mutation had a p53 overexpression. All patientswith a prolonged disease control (TTF1 ≥ 10 months)
had TP53 wildtype tumors, including one patient
whose tumor carried the silent TP53 mutation R248R.
These data of course should be regarded pre-liminary,
but they provide early evidence of a potential import-
ant role for the p53/TP53 status as a biomarker in
patients treated with anti-EGFR agents. This evidence is
supported by recent data presented at the 2013 European
Cancer Congress on neoadjuvant cetuximab-containing
chemoradiotherapy (CRT) in locally advanced rectal
cancer: translational data from a subgroup of patients
(n = 144) treated within the EXPERT-C trial showed that
the TP53 mutation status might serve as an independent
predictive biomarker for cetuximab efficacy [24]. In
detail, for TP53 wildtype patients (48%) the addition of
cetuximab to CRT was associated with a statistically
significant advantage in PFS (HR 0.23, p = 0.02) and OS
(HR 0.16, p = 0.02). In multivariate analyses, this interaction
Table 4 TP53 mutation analysis [exon 5–8] in 12 selected good- and poor-risk study patients from AIO-PK0104
(in correlation with KRAS status and p53 IHC)
Case Exon 5 Exon 6 Exon 7 Exon 8 p53 expression by IHC KRAS status (Exon 2) Best response by imaging (RECIST) TTF1 [Mo.]
198 wt wt wt wt regular wt PR 19.1
8 n.a. n.a. R249S n.a. n.a. mut SD 6.0
197 n.a. wt n.a. wt Regular mut PD 1.8
60 n.a. wt n.a. wt n.a. mut PR 6.3
89 wt wt wt wt n.a. wt SD 9.8
64 wt wt wt wt n.a. mut SD 10.0
50 n.a. D208N wt wt n.a. mut PD 2.0
33 n.a. wt R248R* wt n.a. mut SD 19.6
134 V147I wt wt wt Overexpression mut SD 3.9
132 n.a. wt wt V274I Overexpression mut PD 2.2
99 T155I & wt wt wt n.a. mut PD 0.5
V137M
98 wt wt wt wt n.a. wt PD 1.7
Abbreviations: IHC Immunohistochemistry, Mo Months, mut Mutation, PD Progressive disease, PR Partial response, SD Stable disease, TTF1 Time-to-treatment failure
after 1st-line therapy, wt Wildtype.
(*silent mutation).
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prognostic factors and KRAS status. In contrast, for
TP53 mutant patients (52%) no improvement in survival
endpoints was observed for the addition of cetuximab to
neoadjuvant CRT [24].
The main limitation from our current retrospective
translational study arises from the fact that only a subgroup
of the study patients could be analyzed for the biomarkers
pERK, pAKT and p53. This circumstance mainly is based
on the fact that tumor samples were limited in our study
collective (specifically after already having performed
detailed molecular analyses on KRAS, EGFR and PTEN
[10]), a persisting and well known hurdle for many
international collaborative groups that conduct translationalTable 5 Correlation of biomarkers results with the
occurrence of skin rash (any grades, I-III)
Biomarker n Skin rash [%] p
No rash Any rash (grade I-III)
p-ERK 153
pERKlow 55 29 71 0.41
pAKThigh 98 36 64
p-AKT 35
pERKlow 21 33 67 0.49
pAKThigh 14 46 54
p53 50
Loss 4 75 25 0.04+
Regular 20 16 84
Overexpression 26 39 61
(+gobal p value).research in advanced pancreatic cancer [25]. In light of the
small sample size, specifically the data on pAKT and p53
should be regarded carefully and hypothesis-generating
only and they clearly need prospective validation in a larger
cohort of patients. Additionally one should also keep in
mind that the assessment of an IHC-based scoring system
may have several methodological limitations, specifically
when analyzing categorical data by using predefined
cut-offs (that often themselves have no clear biological
rationale). We tried to overcome some of these limitations
by analyzing our pERK data as continuous variable
(see Figure 1); an approach that possibly better reflects the
biological function of a molecular marker compared
to results obtained when dichotomizing biomarker data
(e.g. high vs low or positive vs negative, respectively).
The investigators are aware of the fact that the clinical
value of adding erlotinib to standard gemcitabine is limited
in an unselected patient population with metastatic
pancreatic cancer. This specifically holds true in the
context of recent phase III data on FOLFIRINOX and
nab-paclitaxel, that both provide a meaningful and relevant
advance in the treatment of pancreatic adenocarcinoma
[26,27]. Nevertheless, there is a subgroup of patients that
derives a clinically relevant benefit of adding erlotinib to
gemcitabine, namely those patients that develop skin
rash during treatment. In these patients, median survival
times of about 10 months can be expected - a time
frame that is in the same range of the FOLFIRINOX
or gemcitabine/nab-paclitaxel data [4,7,26,27]. Up to now,
we unfortunately are not able to molecularly define this
scientifically interesting subgroup and the authors thus
believe that pancreatic cancer researchers should continue
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derive benefit from EGFR-targeting agents in this harmful
disease. In this context, some novel hypothesis-generating
findings could be obtained by the current translational
analysis of AIO-PK0104; however, as these results will
currently have no direct impact on clinical practice, a
prospective scientific validation of our pre-liminary
findings is recommended.
Conclusions
For this translational study downstream targets of the
EGFR signalling network, namely pERK and pAKT, were
centrally analyzed together with the tumor suppressor
p53 in erlotinib-treated pancreatic cancer patients: pERK
overexpression showed a negative correlation with OS.
Preliminary results in 50 patients analysed for p53
expression suggested an improvement in PFS and a higher
rate of skin rash in patients whose tumors had a regular
p53 expression compared to patients with a complete loss
of p53. Our findings thus suggest that both pERK and p53
may serve as prognostic and/or predictive biomarkers in
erlotinib-treated advanced pancreatic cancer.
Additional files
Additional file 1: Table S1. List of ethical committees List of German
ethical committees that approved the AIO-PK0104 study.
Additional file 2: Figure S1. Immunohistochemistry staining for pERK
in tissue specimens from AIO-PK0104. A Moderate pERK staining in
pancreatic adenocarcinoma cells (score 4); B Strong pERK staining in
pancreatic adenocarcinoma cells (score 9); (magnification x 200, for all figures).
Additional file 3: Figure S2. Immunohistochemistry staining for p53 and
pAKT in tissue specimens from AIO-PK0104. A No p53 staining in pancreatic
adenocarcinoma cells with positive internal control (inflammatory cells,
arrows), considered as complete loss of p53; B varying expression of p53 in
tumor cells, considered as regular p53 expression; C strong homogenous
p53 expression, considered as p53 overexpression (corresponding to
mutation in p53); D weak nuclear pAKT expression; E strong nuclear pAKT
reaction in tumor cells; F strong nuclear pAKT expression with additional
cytoplasmic staining; (magnification x 200, for all figures).
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